Medtronic PLC (MDT)
Official siteHEALTHCARE • MEDICAL DEVICES • NYSE
Market Cap: $131.57B
Last updated: Nov 17, 2026 at 11:06 AM ET
Medtronic PLC (MDT) Earnings: Report Dates and Results
Medtronic (MDT) is confirmed to report earnings on Nov 24, 2026, before the open. In the quarter ended Jul 31, 2026, Medtronic reported EPS of $1.45, above the $1.39 estimate. It beat the EPS estimate in each of the last 17 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MDT has a confirmed report date of Nov 24, 2026, before the open. Analysts' consensus for the quarter ended Oct 31, 2026 is 2.2% below the $1.36 reported for the quarter ended Oct 31, 2025.
MDT Earnings Call
The latest MDT earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MDT beat 36, missed 2 and matched 2. Revenue for the quarter ended Jul 31, 2026 was $9.76B, up 13.8% from $8.58B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 | $1.45 | $1.39 | $1.37 - $1.40 | +4.32% | Beat | +15.1% | 24 | 1 up, 1 down | Sep 1, 2026 | $9.76B |
| Apr 30, 2026 | $1.55 | $1.54 | $1.52 - $1.66 | +0.65% | Beat | -4.3% | 21 | 0 up, 2 down | Jun 3, 2026 | $9.81B |
| Jan 31, 2026 | $1.36 | $1.34 | $1.33 - $1.36 | +1.49% | Beat | -2.2% | 26 | 0 up, 4 down | Feb 17, 2026 | $9.02B |
| Oct 31, 2025 | $1.36 | $1.31 | $1.31 - $1.32 | +3.82% | Beat | +7.9% | 26 | 0 up, 1 down | Nov 18, 2025 | $8.96B |
| Jul 31, 2025 | $1.26 | $1.23 | $1.22 - $1.24 | +2.44% | Beat | +2.4% | 24 | 2 up, 0 down | Aug 19, 2025 | $8.58B |
| Apr 30, 2025 | $1.62 | $1.58 | $1.56 - $1.59 | +2.53% | Beat | +11.0% | 27 | 1 up, 0 down | May 21, 2025 | $8.93B |
| Jan 31, 2025 | $1.39 | $1.36 | $1.35 - $1.37 | +2.21% | Beat | +6.9% | 26 | 1 up, 1 down | Feb 18, 2025 | $8.29B |
| Oct 31, 2024 | $1.26 | $1.25 | $1.23 - $1.27 | +0.80% | Beat | +0.8% | 28 | 1 up, 1 down | Nov 19, 2024 | $8.40B |
| Jul 31, 2024 | $1.23 | $1.20 | $1.18 - $1.21 | +2.50% | Beat | +2.5% | 28 | 1 up, 0 down | Aug 20, 2024 | $7.92B |
| Apr 30, 2024 | $1.46 | $1.45 | $1.44 - $1.46 | +0.69% | Beat | -7.0% | 27 | 0 up, 0 down | May 23, 2024 | $8.59B |
| Jan 31, 2024 | $1.30 | $1.26 | $1.25 - $1.27 | +3.17% | Beat | 0.0% | 27 | 0 up, 0 down | Feb 20, 2024 | $8.09B |
| Oct 31, 2023 | $1.25 | $1.18 | $1.16 - $1.20 | +5.93% | Beat | -3.8% | 27 | 1 up, 0 down | Nov 21, 2023 | $7.98B |
| Jul 31, 2023 | $1.20 | $1.11 | $1.10 - $1.13 | +8.11% | Beat | +6.2% | 27 | 1 up, 0 down | Aug 22, 2023 | $7.70B |
| Apr 30, 2023 | $1.57 | $1.55 | $1.54 - $1.57 | +1.29% | Beat | +3.3% | 25 | 1 up, 0 down | May 25, 2023 | $8.54B |
| Jan 31, 2023 | $1.30 | $1.27 | $1.25 - $1.32 | +2.36% | Beat | -5.1% | 23 | 1 up, 1 down | Feb 21, 2023 | $7.73B |
| Oct 31, 2022 | $1.30 | $1.28 | $1.25 - $1.29 | +1.56% | Beat | -1.5% | 25 | 0 up, 1 down | Nov 22, 2022 | $7.58B |
| Jul 31, 2022 | $1.13 | $1.12 | $1.10 - $1.16 | +0.89% | Beat | -19.9% | 23 | 0 up, 1 down | Aug 23, 2022 | $7.37B |
| Apr 30, 2022 | $1.52 | $1.56 | $1.54 - $1.57 | -2.56% | Miss | +1.3% | 23 | 0 up, 1 down | May 26, 2022 | $8.09B |
| Jan 31, 2022 | $1.37 | $1.37 | $1.34 - $1.38 | 0.00% | In line | +6.2% | 13 | 0 up, 4 down | Feb 22, 2022 | $7.76B |
| Oct 31, 2021 | $1.32 | $1.29 | $1.27 - $1.30 | +2.33% | Beat | +29.4% | 22 | N/A | Nov 23, 2021 | $7.85B |
| Jul 31, 2021 | $1.41 | $1.32 | $1.31 - $1.37 | +6.82% | Beat | +127.4% | 25 | N/A | Aug 24, 2021 | $7.99B |
| Apr 30, 2021 | $1.50 | $1.42 | $1.39 - $1.48 | +5.63% | Beat | +158.6% | 26 | N/A | May 27, 2021 | $8.19B |
| Jan 31, 2021 | $1.29 | $1.15 | $1.11 - $1.24 | +12.17% | Beat | -10.4% | 23 | N/A | Feb 23, 2021 | $7.78B |
| Oct 31, 2020 | $1.02 | $0.80 | $0.71 - $1.02 | +27.50% | Beat | -22.1% | 22 | N/A | Nov 24, 2020 | $7.65B |
| Jul 31, 2020 | $0.62 | $0.18 | -$0.02 - $0.42 | +244.44% | Beat | -50.8% | 20 | N/A | Aug 25, 2020 | $6.51B |
| Apr 30, 2020 | $0.58 | $0.75 | $0.12 - $1.63 | -22.67% | Miss | -62.3% | 23 | N/A | May 21, 2020 | $6.00B |
| Jan 31, 2020 | $1.44 | $1.38 | $1.38 - $1.39 | +4.35% | Beat | +11.6% | 23 | N/A | Feb 18, 2020 | $7.72B |
| Oct 31, 2019 | $1.31 | $1.28 | $1.27 - $1.30 | +2.34% | Beat | +7.4% | 21 | N/A | Nov 19, 2019 | $7.71B |
| Jul 31, 2019 | $1.26 | $1.19 | $1.18 - $1.20 | +5.88% | Beat | +7.7% | 21 | N/A | Aug 20, 2019 | $7.49B |
| Apr 30, 2019 | $1.54 | $1.47 | $1.43 - $1.48 | +4.76% | Beat | +8.5% | 25 | N/A | May 23, 2019 | $8.15B |
| Jan 31, 2019 | $1.29 | $1.24 | $1.22 - $1.25 | +4.03% | Beat | +10.3% | 25 | N/A | Feb 19, 2019 | $7.55B |
| Oct 31, 2018 | $1.22 | $1.15 | $1.14 - $1.16 | +6.09% | Beat | +14.0% | 23 | N/A | Nov 20, 2018 | $7.48B |
| Jul 31, 2018 | $1.17 | $1.11 | $1.10 - $1.13 | +5.41% | Beat | +4.5% | 22 | N/A | Aug 21, 2018 | $7.38B |
| Apr 30, 2018 | $1.42 | $1.39 | $1.37 - $1.40 | +2.16% | Beat | +6.8% | 21 | N/A | May 24, 2018 | $8.14B |
| Jan 31, 2018 | $1.17 | $1.17 | $1.15 - $1.18 | 0.00% | In line | +4.5% | 21 | N/A | Feb 20, 2018 | $7.37B |
| Oct 31, 2017 | $1.07 | $1.03 | $0.87 - $1.09 | +3.88% | Beat | -4.5% | 21 | N/A | Nov 21, 2017 | $7.05B |
| Jul 31, 2017 | $1.12 | $1.08 | $1.07 - $1.12 | +3.70% | Beat | +8.7% | 22 | N/A | Aug 22, 2017 | $7.39B |
| Apr 30, 2017 | $1.33 | $1.31 | $1.29 - $1.34 | +1.53% | Beat | +4.7% | 20 | N/A | May 25, 2017 | $7.92B |
| Jan 31, 2017 | $1.12 | $1.11 | N/A | +0.90% | Beat | +5.7% | N/A | N/A | Feb 21, 2017 | $7.28B |
| Oct 31, 2016 | $1.12 | $1.11 | N/A | +0.90% | Beat | +8.7% | N/A | N/A | Nov 22, 2016 | $7.34B |
Annual EPS
EPS for the fiscal year ended Apr 30, 2026 was $5.53, within 4 cents of the year before. It was $4.60 for the year ended Apr 30, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Apr 30, 2026 | $5.53 | N/A |
| Apr 30, 2025 | $5.50 | +5.6% |
| Apr 30, 2024 | $5.21 | -1.7% |
| Apr 30, 2023 | $5.30 | -5.7% |
| Apr 30, 2022 | $5.62 | +26.9% |
| Apr 30, 2021 | $4.43 | -3.5% |
| Apr 30, 2020 | $4.59 | -12.1% |
| Apr 30, 2019 | $5.22 | +9.2% |
| Apr 30, 2018 | $4.78 | +3.9% |
| Apr 30, 2017 | $4.60 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,400 words across 14 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 5,358 | 14 | |
| 2026Q2 | Jun 30, 2026 | 9,563 | 11 | |
| 2026Q1 | Mar 31, 2026 | 8,512 | 14 | |
| 2025Q4 | Dec 31, 2025 | 9,441 | 16 | |
| 2025Q3 | Sep 30, 2025 | 8,253 | 16 | |
| 2025Q2 | Jun 30, 2025 | 7,665 | 19 | |
| 2025Q1 | Mar 31, 2025 | 7,374 | 19 | |
| 2024Q4 | Dec 31, 2024 | 8,521 | 15 |
2026Q3 Earnings Call
Opening remarks
Geoffrey Martha Chief Executive Officer Beyond cash, we're also making material progress with Symplicity for hypertension and Altaviva for urge urinary incontinence. Symplicity delivers a one-time durable minimally invasive treatment for hypertension and represents one of our largest growth drivers. This is going to be a contributor for years to come given the 18 million U.S. patients with uncontrolled hypertension. We're seeing strong patient outcomes in the field and the value proposition resonates with both physicians and patients. We have strong and growing clinical data, a broad label and expanding reimbursement all in hand. We've built the foundation. Now we're focused on growing this new segment and transforming the hypertension treatment paradigm. We've recently activated our direct-to-consumer Go Beyond campaign in key markets around the U.S., which is resulting in a 50x increase in website visits versus the prior quarter. So a lot of interest coming in from patients. Building a new market takes time, but that is something Medtronic knows how to do exceptionally well. In parallel to building out this new market, we're innovating for the long term. First, with our transradial catheter, which is on track to launch in the second half of fiscal year '27, and with our Spiral Gemini trial evaluating multi-organ ablation to further boost efficacy. Similarly, we are scaling Altaviva, our tibial neurostimulation device. Altaviva is a simple yet transformational option for treating urge urinary incontinence, a condition that affects about 1 million people in the U.S. Altaviva is a very small device that requires no imaging, no sedation, activates the same day, is MRI ready and offers up to 15 years of battery life, the longest in its category. We are receiving great early interest and feedback from both physicians and patients. We are training doctors, educating and supporting hospital staff and investing in omnichannel consumer activation. It's early days for both of these launches, and we are focused on disciplined execution to convert early traction into procedures. Pivoting to Hugo. This quarter, our Hugo robot received FDA clearance for urologic surgical procedures, enabling us to begin our purposeful U.S. launch. Today, I'm excited to share that we've already completed our first installations and initial cases. As noted in our release this morning, last week we completed our first cases at Cleveland Clinic, where surgeons echoed the strong feedback we continuously receive on Hugo's differentiation across multiple areas. This includes its flexibility, portability, open console and, of course, our trusted instrumentation. Hugo is especially compelling when paired with our Touch Surgery Digital Ecosystem, an AI-powered data connectivity and analytics technology that is unique to Medtronic. This quarter, Touch Surgery installations increased over 20% sequentially and have now surpassed 1,000 systems globally.
Frequently Asked Questions About MDT
When is Medtronic's next earnings date?
Medtronic's next earnings report is confirmed for Nov 24, 2026, before the open.
Did MDT beat earnings estimates last quarter?
Yes. Medtronic reported EPS of $1.45 for the quarter ended Jul 31, 2026, above the $1.39 estimate, a 4.32% surprise.
What EPS do analysts expect from MDT next quarter?
The consensus EPS estimate for Medtronic for the quarter ended Oct 31, 2026 is $1.33 from 25 analysts, with estimates from $1.32 to $1.34.
How often does MDT beat earnings estimates?
Medtronic beat the EPS estimate in each of the last 17 quarters, with an average surprise of +2.63%.
Does MDT report before or after the market opens?
Medtronic is confirmed to report on Nov 24, 2026, before the market opens.
MDT pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts